Founded in 1968, today Lupin is India's second largest pharmaceuticals company, and the 14th largest generic pharmaceutical company in the world. Products sold in 70 countries.
This company received an S&P Global ESG Score of 11/100 in the Pharmaceuticals category of the 2019 SAM Corporate Sustainability Assessment, an annual evaluation of companies' sustainability practices. The rankings are based on an analysis of corporate economic, environmental and social performance, assessing issues such as corporate governance, risk management, environmental reporting, climate strategy, human rights and labour practices.
Source: S&P Global (2019)
The European Commission imposed fines totalling 427.7m Euros on the French pharmaceutical company Servier and five producers of generic medicines, including Lupin Ltd, for concluding a series of deals aimed at protecting Servier's best selling blood pressure medicine, perindopril, from price competition by generics in the European Union. Lupin Ltd was fined 40m euros.
Source: European Commission (2014)
The Lupin Human Welfare & Research Foundation (LHWRF) was set up in 1988 with the stated mission "to provide an alternative model of rural development which is sustainable, replicable and ever evolving essentially empowering under privileged and marginalized sections of society and providing basic infrastructure and balanced ecological base to the villages."
Source: company website (2014)
|Company Structure||Public company|
|Revenue||US$1.7 billion in 2013|
|# Employees||12,984 in 2014|
|Subsidiaries||Generic Health Pty Ltd (91% owned)|